Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT01602939
Other study ID # EC11-187
Secondary ID
Status Recruiting
Phase Phase 2/Phase 3
First received May 16, 2012
Last updated August 26, 2016
Start date May 2012
Est. completion date June 2017

Study information

Verified date August 2016
Source Hospital Virgen de la Salud
Contact Luis Escribano, MD, PhD
Phone +34925269335
Email lescribanom@sescam.jccm.es
Is FDA regulated No
Health authority Spain: Ministry of Health
Study type Interventional

Clinical Trial Summary

The aim of this study is to evaluate the efficacy in terms of clinical and biological response rates of Cladribine plus Pegylated Interpheron alpha-2a therapy in patients with advanced systemic mastocytosis carrying D816V or other exon 17 KIT mutations.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date June 2017
Est. primary completion date February 2017
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Age older than 18 years.

- Diagnosis of advanced systemic mastocytosis (aggressive systemic mastocytosis or proggressing systemic mastocytosis) with D816V or other exon 17 KIT mutations.

- ECOG = 3.

- Signed informed consent.

Exclusion Criteria:

- Impaired liver function (total bilirubin = 2.0 mg/dl, AST or ALT > 3 x upper limit of normal)not related to mastocytosis.

- Impaired renal function (= 2.0 mg/dL)not related to mastocytosis.

- Grade III-IV cytopenias not related to mastocytosis. Severe cardiopathy (grade III/IV of NYHA, or left ventricular ejection fraction < 50%).

- Pregnancy or breastfeeding.

- Female patients who do not use contraceptive methods.

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Cladribine and pegylated interpheron alpha-2a
Cladribine (0.07 mg/Kg/day) s.c for 5 consecutive days each month for a total of 6 months.Cladribine daily doses could be increased up to 0.14 mg/Kg in the fourth, fifth and sixth cycles of therapy if no objetive response is achieved after the third cycle. Pegylated Interpheron alpha-2a (1 mcgr/Kg) s.c weekly for a total of 6 months.

Locations

Country Name City State
Spain Instituto de Estudios de Mastocitosis de Castilla La Mancha; Hospital Virgen del Valle Toledo

Sponsors (1)

Lead Sponsor Collaborator
Hospital Virgen de la Salud

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary To evaluate the effect of therapy on bone marrow mast cell infiltration. Evaluation of bone marrow response will be assessed by immunohistochemestry, citology, flow cytometry and molecular analyses of bone marrow samples. 6 months No
Secondary To determine the effect of therapy on serum tryptase levels and other altered peripheral blood parameters due to mastocytosis. Serum tryptase and any other mastocytosis-related altered biochemical parameter at diagnosis will be measured monthly until the end of therapy. 6 months No
Secondary To evaluate the effect of therapy on mast cell-mediator release symptoms: pruritus, flushing, gastrointestinal symptoms or anaphylaxis). Specific questionnaires regarding mast cell-mediator release symptoms will be filled monthly by each patient until the end of therapy. 6 months No
Secondary To determine de safety of combined therapy with low doses of cladribine plus pegylated interpheron alpha-2a. Potentially drugs-related adverse events will be recorded in each case following accepted criteria (NIH CTCAE). 6 months Yes
Secondary To evaluate the effect of therapy on mastocytosis skin lesions. Evaluation of cutaneous response will be assessed by macroscopic inspection including photographs and by skin immunohistochemestry. 6 moths No
Secondary To evaluate the effect of therapy on mastocytosis-related organomegalies. Evaluation of organomegalies response will be assessed by abdominal ultrasound and/or computerized tomography. 6 months No
Secondary To evaluate the effect of therapy on mastocytosis-related bone alterations. Evaluation of bone response will be assessed by X-ray survey and/or computerized tomography. 6 months No
See also
  Status Clinical Trial Phase
Completed NCT01807598 - Brentuximab Vedotin in Treating Patients With Advanced Systemic Mastocytosis or Mast Cell Leukemia Phase 2
Completed NCT00171912 - Imatinib Mesylate in Patients With Various Types of Malignancies Involving Activated Tyrosine Kinase Enzymes Phase 2
Completed NCT02441166 - Diagnostic Value of Bone Marrow Tryptase in Systemic Mastocytosis N/A
Withdrawn NCT03739606 - Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer Phase 2
Not yet recruiting NCT00979160 - Evaluation of Response of Dasatinib to Treat Mastocytosis Phase 2
Active, not recruiting NCT04681105 - Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies Phase 1
Completed NCT03401060 - Interest of Denosumab Treatment in Osteoporosis Associated to Systemic Mastocytosis Phase 3
Terminated NCT02415608 - Ibrutinib in Treating Patients With Advanced Systemic Mastocytosis Phase 2
Completed NCT02478957 - Treatment of Indolent Systemic Mastocytosis With PA101 Phase 2
Terminated NCT00918931 - Obatoclax for Systemic Mastocytosis Phase 2
Completed NCT00493129 - Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM) Phase 2
Completed NCT01297777 - Imatinib in KIT-negative Systemic Mastocytosis Phase 4
Terminated NCT03214666 - GTB-3550 Tri-Specific Killer Engager (TriKE®) for High Risk Hematological Malignancies Phase 1/Phase 2
Completed NCT01334996 - Use of Tamoxifen in Systemic Mastocytosis
Completed NCT00449748 - Everolimus (RAD001) as Therapy for Patients With Systemic Mastocytosis Phase 2
Completed NCT00109707 - A Study of Oral AMN107 in Adults With Chronic Myelogenous Leukemia (CML) or Other Hematologic Malignancies Phase 1/Phase 2